Options Corner: Sanofi's Post-Earnings Drama Delivers A Contrarian Discount Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential contrarian discount.
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline.
Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose preclinical studies.
Why Thermo Fischer Stock Is Rising Wednesday Thermo Fisher beat Q2 estimates, raised its 2025 guidance, and announced a CFO transition as easing tariffs support an improved outlook.
Humana Moves To Cut Prior Authorization Delays, Streamline Care Approvals Humana will cut prior authorizations, launch a gold card program, and speed up electronic approvals to improve care access and transparency by 2026.
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.
Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal standards by the trial judge.
Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025.
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher? Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.
Why This Biotech Stock Just Doubled In A Single Day Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday? Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
Why Is Cidara Therapeutics Stock Trading Higher On Monday? Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3.
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results.
Analysts Can't Get Enough of These Little-Known Biopharma Stocks Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.
Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older.
